SG Americas Securities LLC Has $160,000 Stake in Amicus Therapeutics, Inc. (FOLD)

SG Americas Securities LLC reduced its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 61.7% during the first quarter, Holdings Channel reports. The fund owned 22,398 shares of the biopharmaceutical company’s stock after selling 36,035 shares during the period. SG Americas Securities LLC’s holdings in Amicus Therapeutics were worth $160,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the stock. Princeton Alpha Management LP purchased a new stake in shares of Amicus Therapeutics during the first quarter valued at about $106,000. Creative Planning raised its stake in shares of Amicus Therapeutics by 56.2% in the first quarter. Creative Planning now owns 16,400 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 5,900 shares during the last quarter. Rockefeller Financial Services Inc. purchased a new stake in shares of Amicus Therapeutics during the first quarter valued at about $136,000. Brown Advisory Inc. raised its stake in shares of Amicus Therapeutics by 1.0% in the fourth quarter. Brown Advisory Inc. now owns 32,154 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 304 shares during the last quarter. Finally, Berson & Corrado Investment Advisors LLC raised its stake in shares of Amicus Therapeutics by 16.8% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 47,525 shares of the biopharmaceutical company’s stock valued at $339,000 after buying an additional 6,825 shares during the last quarter.

Amicus Therapeutics, Inc. (FOLD) opened at 10.44 on Monday. The stock has a 50 day moving average price of $8.63 and a 200 day moving average price of $6.95. The stock’s market capitalization is $1.49 billion. Amicus Therapeutics, Inc. has a 12 month low of $4.41 and a 12 month high of $10.77.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.02. The company had revenue of $4.20 million during the quarter, compared to the consensus estimate of $4.16 million. The company’s revenue was up 50.0% compared to the same quarter last year. On average, equities research analysts forecast that Amicus Therapeutics, Inc. will post ($1.45) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “SG Americas Securities LLC Has $160,000 Stake in Amicus Therapeutics, Inc. (FOLD)” was reported by WKRB News and is owned by of WKRB News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.wkrb13.com/markets/2284436/sg-americas-securities-llc-has-160000-stake-in-amicus-therapeutics-inc-fold.html.

Several brokerages have issued reports on FOLD. Robert W. Baird restated an “outperform” rating and issued a $12.00 target price on shares of Amicus Therapeutics in a research note on Friday, June 30th. BidaskClub upgraded Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. ValuEngine upgraded Amicus Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. J P Morgan Chase & Co set a $13.00 target price on Amicus Therapeutics and gave the company a “buy” rating in a research note on Monday, June 5th. Finally, Chardan Capital restated a “buy” rating and issued a $12.50 target price on shares of Amicus Therapeutics in a research note on Thursday, June 1st. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $11.46.

In other Amicus Therapeutics news, insider Hung Do sold 29,914 shares of the firm’s stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $8.00, for a total transaction of $239,312.00. Following the sale, the insider now directly owns 474,438 shares of the company’s stock, valued at $3,795,504. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Jay Barth sold 30,000 shares of the firm’s stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $10.00, for a total value of $300,000.00. Following the sale, the insider now directly owns 64,184 shares in the company, valued at $641,840. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by company insiders.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284436/sg-americas-securities-llc-has-160000-stake-in-amicus-therapeutics-inc-fold.html

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.